US embassy celebrates Nigerian doctor who helped Pfizer develop COVID-19 vaccine
Dargaggeessa Afrikaa dhibee hamaa Yeroo ammaa kana Addunyaa rakkisaa jiruuf talaallii ittisa dhibee sanaa kan harka dhibba keessaa 90 dhibee sanarraa nama Ittisuu danda’u warra argatan keessaa nama tokko ta’uun beekame.
The US embassy in Nigeria has celebrated Onyema Ogbuagbu, a Nigerian-born researcher and medical doctor, for his role in the development of a COVID-19 vaccine.
The vaccine has been tested on 43,500 people in six countries and no safety concerns have been raised. Pfizer was quoted as saying it would be able to supply 50 million doses by the end of 2020, and around 1.3 billion by the end of 2021.
Leading Pfizer research for a COVID-19 vaccine is Ogbuagu with years of medical research experience.
“Nigerians contribute to the world in so many ways. Our hats off to Dr. Onyema Ogbuagbu at Yale who helped develop a COVID-19 vaccine,” the tweet reads.
Nigerians contribute to the world in so many ways. Our hats off to Dr. Onyema Ogbuagbu at Yale who helped develop a COVID-19 vaccine! pic.twitter.com/DYFWHlJSFM
— U.S. Mission Nigeria (@USinNigeria) November 23, 2020
The US embassy, in its recognition of Ogbuagu’s effort, described it as an “incredible contribution to ending this world-wide pandemic”.
Ogbuagu is one of the twin sons of Chibuzo Ogbuagu, a former vice-chancellor of Abia State University, and Stella Ogbuagu, a professor of sociology who was best graduating student of the 1974 class at the University of Nigeria, Nsukka (UNN). His twin brother is an engineer.
He studied medicine at the University of Calabar, Cross River state, in 2003. After graduation, he interned at the Ebonyi State University Teaching Hospital, Abakaliki, before proceeding to the US.
Ogbuagu is an associate professor of medicine in the clinician-educator track and director of the HIV clinical trials programme of the Yale AIDS programme at the Yale School of Medicine.
He is Yale principal investigator on multiple investigational therapeutic and preventative clinical trials for COVID-19, including remdesivir (now FDA approved), leronlimab and remdesivir and tocilizumab combination therapy, as well as the Pfizer/BioNTech vaccine trial.